assays hts tubulin polymerization assay kit cytoskeleton (Cytoskeleton Inc)
96
Structured Review
Cytoskeleton Inc
assays hts tubulin polymerization assay kit cytoskeleton
Assays Hts Tubulin Polymerization Assay Kit Cytoskeleton, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 96/100, based on 97 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/assays+hts+tubulin+polymerization+assay+kit+cytoskeleton/Tubulin+polymerization+assay/pm39970877-347-63-68
Average 96 stars, based on 97 article reviews
Assays Hts Tubulin Polymerization Assay Kit Cytoskeleton, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 96/100, based on 97 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/assays+hts+tubulin+polymerization+assay+kit+cytoskeleton/Tubulin+polymerization+assay/pm39970877-347-63-68
Average 96 stars, based on 97 article reviews
assays hts tubulin polymerization assay kit cytoskeleton - by Bioz Stars,
2026-09
96/100 stars
Images
Related Articles
Recombinant:Article Title: First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors. Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human PCNA Abcam Cat# ab81289; RRID: AB_303394 Anti-human CD34 Abcam Cat# ab29; RRID: AB_1640331 Biological samples Blood Patients in this study N/A Chemicals, peptides, and recombinant proteins DX1002 Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A CA4P Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A 5-FU Shanghai Xudong Haipu Pharmaceutical Co., Ltd N/A Carboplatin Qilu pharmaceutical Co., Ltd. N/A Critical commercial Article Title: First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors Article Snippet: .. Cell Reports Medicine 6, 101969, February 18, 2025 9 Article ll OPEN ACCESS STAR+METHODS KEY RESOURCES TABLE REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human PCNA Abcam Cat# ab81289; RRID: AB_303394 Anti-human CD34 Abcam Cat# ab29; RRID: AB_1640331 Biological samples Blood Patients in this study N/A Chemicals, peptides, and recombinant proteins DX1002 Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A CA4P Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A 5-FU Shanghai Xudong Haipu Pharmaceutical Co., Ltd N/A Carboplatin Qilu pharmaceutical Co., Ltd. N/A Critical commercial Polymerization Assay:Article Title: First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors. Article Snippet: .. REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human PCNA Abcam Cat# ab81289; RRID: AB_303394 Anti-human CD34 Abcam Cat# ab29; RRID: AB_1640331 Biological samples Blood Patients in this study N/A Chemicals, peptides, and recombinant proteins DX1002 Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A CA4P Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A 5-FU Shanghai Xudong Haipu Pharmaceutical Co., Ltd N/A Carboplatin Qilu pharmaceutical Co., Ltd. N/A Critical commercial Article Title: First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors Article Snippet: .. Cell Reports Medicine 6, 101969, February 18, 2025 9 Article ll OPEN ACCESS STAR+METHODS KEY RESOURCES TABLE REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human PCNA Abcam Cat# ab81289; RRID: AB_303394 Anti-human CD34 Abcam Cat# ab29; RRID: AB_1640331 Biological samples Blood Patients in this study N/A Chemicals, peptides, and recombinant proteins DX1002 Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A CA4P Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A 5-FU Shanghai Xudong Haipu Pharmaceutical Co., Ltd N/A Carboplatin Qilu pharmaceutical Co., Ltd. N/A Critical commercial Software:Article Title: First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors Article Snippet: .. Cell Reports Medicine 6, 101969, February 18, 2025 9 Article ll OPEN ACCESS STAR+METHODS KEY RESOURCES TABLE REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human PCNA Abcam Cat# ab81289; RRID: AB_303394 Anti-human CD34 Abcam Cat# ab29; RRID: AB_1640331 Biological samples Blood Patients in this study N/A Chemicals, peptides, and recombinant proteins DX1002 Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A CA4P Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A 5-FU Shanghai Xudong Haipu Pharmaceutical Co., Ltd N/A Carboplatin Qilu pharmaceutical Co., Ltd. N/A Critical commercial Cell Culture:Article Title: First-in-human phase 1 study of an orally bioavailable vascular-disrupting agent DX1002 in patients with advanced solid tumors Article Snippet: .. Cell Reports Medicine 6, 101969, February 18, 2025 9 Article ll OPEN ACCESS STAR+METHODS KEY RESOURCES TABLE REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Anti-human PCNA Abcam Cat# ab81289; RRID: AB_303394 Anti-human CD34 Abcam Cat# ab29; RRID: AB_1640331 Biological samples Blood Patients in this study N/A Chemicals, peptides, and recombinant proteins DX1002 Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A CA4P Guangzhou Anhao Pharmaceuticals Co., Ltd. N/A 5-FU Shanghai Xudong Haipu Pharmaceutical Co., Ltd N/A Carboplatin Qilu pharmaceutical Co., Ltd. N/A Critical commercial |